Fig. 6
Administration of ROS scavenger attenuates JE progression. A–C Increased resistance of BHA-administered mice to JE. Wild-type (WT) C57BL/6 mice (5 to 6 weeks old, n = 10–11) were inoculated i.p. with JEV (7.5 × 107 ffu), and daily oral administration of BHA 300 mpk was conducted from 5 days before infection to the 14th day of monitoring. A, Curve showing survival rate; B, Changes in body weight; C, Encephalitis score. D Ratio of BHA-administered mice showing neurological disorders during JE progression. BHA-administered WT mice were examined for neurological disorders every 6 h from 5 to 12 dpi. E Clinical signs. Clinical signs of BHA-administered WT mice were monitored and scored on day 5, 6, and 7 post-infection. F Viral burden in lymphoid and inflammatory tissues of BHA-administered mice during JE progression. Viral burden in lymphoid (spleen) and inflammatory tissues (brain and spinal cord) of BHA-administered WT mice (n = 5–6) were assessed by real-time qRT-PCR at the indicated time points after JEV infection. Viral RNA load was expressed as viral RNA copy number targeted on JEV NS1 gene per microgram of total RNA. Data show the mean ± SEM of the levels derived from at least 2 individual experiments (n = 5–6). *p < 0.05, **p < 0.01, ***p < 0.001 between the levels derived from WT mice administered with vehicle and BHA